Search for more clinical trials
Three New Methods for Diagnosing Pancreas Cancer
Conditions
Pancreas Cancer
Conditions: official terms
Pancreatic Neoplasms
Study Type
Interventional
Study Phase
N/A
Study Design
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Diagnostic
Intervention
Name: Ultrasound and contrast agent
Type: Procedure
Overall Status
Recruiting
Summary
The purpose of this project is to evaluate and compare three new methods for diagnosis, staging, operability evaluation and treatment control of pancreas cancer. The investigators use contrast-enhanced ultrasound combined with the gastrointestinal hormones Secretin and Cholecystokinin, which triggers the enzyme production of pancreas. The hormones induce an increased metabolism and thus an increased blood flow through healthy pancreas tissue, however, not in tumor tissue. The investigators hope to be able to use this effect diagnostically. The patients included will also have a 64-slice-CT in order to evaluate, if an increased diagnostic safety can be reached compared to an older CT scanning method. All patients will also be examined for the tumor marker CA 19-9. Further, the investigators will examine if contrast-enhanced ultrasound can contribute with information in treatment control after either surgery or medical treatment.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: N/A
Gender: Both
Criteria: Inclusion Criteria:
- suspicion of cancer of the pancreas
- suspicion of cancer of the pancreas
Location
Copenhagen University Hospital
Copenhagen, Denmark
Status: Recruiting
Contact: Hanne S Grossjohann, MD - +45 35453419 - hannesonder@dadlnet.dk
Start Date
February 2005
Completion Date
January 2009
Sponsors
University of Copenhagen
Source
University of Copenhagen
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page